SENATE BILL 144

J1

(PRE–FILED)

By: Senator Feldman
Requested: September 22, 2021
Introduced and read first time: January 12, 2022
Assigned to: Finance

A BILL ENTITLED

AN ACT concerning

Health – Authorization to Prescribe and Administer Amygdalin – Repeal

FOR the purpose of repealing certain provisions of law relating to the prescription, administration, and regulation of amygdalin; and generally relating to amygdalin.

BY repealing
Article – Health – General
Section 18–302
Annotated Code of Maryland
(2019 Replacement Volume and 2021 Supplement)

SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
That the Laws of Maryland read as follows:

Article – Health – General

[18–302.

(a) Except as provided in subsection (b) of this section, a physician may prescribe or administer amygdalin to treat cancer.

(b) (1) A hospital or health facility may not restrict or prohibit the use of amygdalin that a physician, with the consent of a patient, prescribes for or administers to the patient.

(2) (i) The Department may restrict or prohibit the use of amygdalin in the treatment of a patient if, after a hearing, the Department finds that the manner in which the amygdalin is prescribed or administered is harmful to the patient.

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
(ii) The Department shall adopt rules and regulations for hearings under this paragraph.

(c) The Department and the State Board of Pharmacy shall regulate the manufacture, distribution, and sale of amygdalin for use in this State, but only to ensure that the amygdalin is not adulterated, contaminated by microorganisms, or misbranded.

SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect October 1, 2022.